For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240403:nRSC1814Ja&default-theme=true
RNS Number : 1814J Axis Bank Limited 03 April 2024
AXIS/CO/CS/3/2024-25
April 3, 2024
Dear Sir(s),
REF.: DISCLOSURE UNDER REGULATION 30 OF SEBI (LISTING OBLIGATIONS AND
DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 ("SEBI LISTING REGULATIONS")
SUB.: UPDATE ON SUSBCRIPTION TO EQUITY SHARES OF MAX LIFE INSURANCE COMPANY
LIMITED
This is with reference to our earlier disclosure letter AXIS/CO/CS/253/2023-24
dated August 9, 2023, informing the exchanges about the proposed infusion of
Rs. 1,612 crore by Axis Bank Limited ("the Bank") in Max Life Insurance
Company Limited ("Max Life"), subject to regulatory approvals.
In this regard, we would like to inform you that the Competition Commission of
India ("CCI") has, vide its letter dated April 2, 2024, intimated that CCI, at
its meeting held on April 2, 2024, considered the proposed combination and
approved the subscription to 14,25,79,161 equity shares of Max Life by the
Bank under subsection (1) of Section 31 of the Competition Act, 2002.
Approval for the aforesaid transaction from the Insurance Regulatory and
Development Authority of India and the Pension Fund Regulatory and Development
Authority was received by Max Life through the letters dated February 6, 2024,
and November 10, 2023, respectively.
With this, all the required regulatory approvals for the proposed subscription
have been received.
This is for your information and records.
Thanking You.
Yours faithfully,
For Axis Bank Limited
Sandeep Poddar
Company Secretary
http://www.rns-pdf.londonstockexchange.com/rns/1814J_1-2024-4-3.pdf
(http://www.rns-pdf.londonstockexchange.com/rns/1814J_1-2024-4-3.pdf)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END ACQFXLFBZZLBBBV